ERBB2 and breast carcinoma: To validate the workflow and the accompanying PBMC-CTC classification system, we processed peripheral blood samples of three HER2-, stage IV breast cancer patients (identified as P3, P4, P5) through the microfluidic device ensemble (Methods, Supplementary Figure S8).